Biomunex CSO Defines Lead Compounds, Early R&D Plans
Executive Summary
Eugene Zhukovsky, chief scientific officer at Biomunex, talks about the company's clinical development strategy of using monospecific antibodies as building blocks for next generation cancer therapies.